Grifols | GRFS - Current Liabilities


Grifols reported EUR2.53B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 921K 153K Sep/2025
Arca Biopharma USD 20.97M 8.86M Sep/2025
aTyr Pharma USD 15.68M 148K Sep/2025
Bio Path USD 7.86M 3.12M Jun/2025
Brainstorm Cell Therapeutics USD 9.02M 495K Sep/2025
Capricor Therapeutics USD 28.15M 249K Sep/2025
Cara Therapeutics USD 10.68M 9.48M Jun/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Grifols EUR 2.53B 182.67M Sep/2025
Immunic USD 30.08M 2.77M Sep/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.67M 143K Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024